Beavatkozás neve: etanercept Leírás: Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter. Age 19 years or above 3. Candidate for systemic treatment in the opinion of the investigator 5.
Willingness to undergo treatment with Enbrel as outlined above 6. Negative pregnancy test urine or serum β-Human Chorionic Gonadotrophin before the first dose of study drug in all women except those surgically sterile, or at least 5 years postmenopausal. Negative Tuberculosis skin test at entry into the study or a negative screening x-ray in inconclusive Purified Protein Derivative reading borderline, reactive but non-diagnostic or in prior bacille Calmette-Guerin inoculated subjects.
Sexually active subjects of childbearing potential must agree to use medically acceptable form of contraception during screening and throughout the study 9. Subject or designee must have the ability to self-inject study medication or have a care giver at home who can administer subcutaneous injections Must be able and willing does alcohol cause psoriasis give written informed consent and comply with the requirements of the study protocol and must authorize release and use of protected health information Exclusion Criteria: 1.
Systemic therapy use e. Topical therapy use e.
Subject is currently enrolled in another investigational device or drug trial sor subject has received other investigational agent s within 28 days of baseline visit. Subjects who have known hypersensitivity to Enbrel or any of its components or who is known to have antibodies to etanercept Prior or concurrent cyclophosphamide therapy Concurrent sulfasalazine therapy Known Human immunodeficiency virus-positive status or known history of any other immunosuppressing disease Active severe infections within 4 weeks before screening visit, or between the screening and baseline visits Untreated Lyme disease Pregnant or lactating females Use of a live vaccine 90 days prior to, or during this study Any condition judged by the patient's physician to cause this clinical trial to be detrimental to the patient History of non-compliance with other therapies Nem:.